The new Biden administration has started off strong, taking a thoughtful approach to any number of critical health care issues and pulling back a number of new regulations to take a fresh look at these public policy issues. To avoid
COVID-19: Frequently Asked Questions PBMs have substantial experience helping patients get the drugs and vaccines they need, including in times of crisis. PBMs are taking action to help educate the patients we serve about the safety and efficacy of authorized
The Visante study highlights top selling Medicare Part D brand-name drugs with steady price increases and no change in rebate levels over a five-year period from 2012 to 2017. In addition, the study analyzes a number of Medicare Part B
(Washington, D.C.) — Today, the U.S. House of Representatives passed a legislative package, SUPPORT for Patients and Communities Act (H.R. 6), which requires electronic prescribing (e-prescribing) of controlled substances in Medicare. This is an important step in the fight against America’s
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) released the following statement on a Medicare Part D report released today by the Office of Inspector (OIG), U.S. Department of Health and Human Services (HHS): “This report finally debunks the myth
In case you missed it, Johnny Garcia, PharmD, Senior Director, Policy at the Pharmaceutical Care Management Association (PCMA), explains the critical role pharmacy benefit companies play in supporting all members of the prescription drug supply chain, including retail pharmacies, in
A recent blog (“Payers and PBMs Profit from Obscure Pharmacy Fees, While Seniors See No Relief in Prescription Costs”) suggests performance-based price concessions are retained by PBMs, restrict the growth of independent pharmacies, and inflate Medicare Part D enrollee’s out-of-pocket costs—unfounded
ISSUE: Fulfilling our commitment to Health Equity Pharmacy benefit companies, in collaboration with plan sponsors, clinicians, and government programs, have a long history of working to advance health equity; however, the severity of the health disparities revealed during the COVID-19
With a nod to Dickens given that it’s the holidays, I’ve been thinking about biosimilars past, present and future lately. In that holiday spirit, even though the parallels aren’t perfect to the classic holiday story, let’s look at the biosimilar
(Washington, D.C.) — As independent drugstore lobbyists descend on Harrisburg for their lobby day, the Pharmaceutical Care Management Association (PCMA) released the following statement: “Pharmacy benefit managers (PBMs) advocate on behalf of Pennsylvania’s consumers and health plan sponsors by negotiating with drug manufacturers and
©2024 PCMA. All Rights Reserved.
